Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen

Autor: Jacobus Burggraaf, Irving Sivin, Joël Ménard, Regine Sitruk-Ware, Barbara A. Tokay, Marieke L. de Kam, Mandana Rad, Cornelis Kluft
Přispěvatelé: TNO Kwaliteit van Leven
Rok vydání: 2007
Předmět:
systolic blood pressure
Biomedical Research
vein disease
Angiotensinogen
Ethinyl Estradiol
low density lipoprotein cholesterol
Sex hormone-binding globulin
high density lipoprotein cholesterol
Sex Hormone-Binding Globulin
estrogen
Contraceptive Agents
Female
Levonorgestrel
media_common
education.field_of_study
biology
adult
hormonal contraception
article
Obstetrics and Gynecology
contraceptive agent
clinical trial
Blood Proteins
sex hormone binding globulin
Blood proteins
Contraceptives
Oral
Combined
female
Cholesterol
liver protein
Female
triacylglycerol
Norprogesterones
hormones
hormone substitutes
and hormone antagonists
medicine.drug
Adult
medicine.medical_specialty
ethinylestradiol plus norelgestromin
Adolescent
Contraceptive vaginal ring
medicine.drug_class
media_common.quotation_subject
Population
artery disease
menstrual cycle
ethinylestradiol plus levonorgestrel
elcometrine
Internal medicine
Ethinylestradiol
Nestorone®
medicine
Humans
controlled study
human
normal human
SHBG
intermethod comparison
education
Menstrual Cycle
Triglycerides
Menstrual cycle
controlled clinical trial
vagina ring
business.industry
Cholesterol
HDL
diastolic blood pressure
Contraceptive Devices
Female
Cholesterol
LDL
Endocrinology
Reproductive Medicine
Estrogen
Hormonal contraception
drug blood level
randomized controlled trial
biology.protein
business
Zdroj: Contraception, 6, 75, 430-437
ISSN: 0010-7824
DOI: 10.1016/j.contraception.2007.01.027
Popis: Objective: We evaluated the effects of a new combined hormonal contraceptive vaginal ring (CVR) delivering the nonandrogenic progestin Nestorone® (NES) and ethinyl estradiol (EE) on several key estrogen-sensitive hepatic proteins that may be markers for the risk of arterial or venous disease events and on blood pressure (BP). Because the pharmacologic androgenicity of the progestin in these formulations influences the hepatic impact of EE, we selected an oral contraceptive (OC) delivering the androgenic progestin levonorgestrel (LNG) and EE as the comparator. We also investigated the effect of delivery route, which is known to modify the hepatic effects of estradiol, but has not been widely studied with EE. Study Methods: Women, aged 18-34 years, with no contraindications to the use of combined OCs, were randomized to three cycles of treatment with a CVR delivering NES/EE (150/15 μg/day) or a combined OC providing LNG and EE (150/30 μg per tablet). Each cycle consisted of 21 days of active treatment, followed by 7 days without treatment. During the last weeks of the pretreatment and third treatment cycles, blood samples were obtained for determinations of plasma concentrations of angiotensinogen, an estrogen-sensitive hepatic protein, and serum concentrations of sex hormone-binding globulin (SHBG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and estrogen- and androgen-sensitive proteins. BP was also measured. Results: Of 47 women randomized, 45 completed the study (CVR: 23; OC: 22). Within-group comparisons over time by repeated-measure analysis of variance demonstrated statistically significant changes over time with both treatments for all hepatic proteins (p
Databáze: OpenAIRE
Externí odkaz: